IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer

PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer. Dr. Kerstein brings to IDRx deep experience in early- and late-stage oncology drug development, including multiple precision oncology medicines. He joins the founding IDRx R&D leadership team of Jessica Christo, Chief Development Operati